Sellas Life Sciences: 78 Events Down, Two to Go — The Trial That Will Settle the Bulls vs. Bears Standoff
Published on 07/04/2026 at 17:47 | Redaktion boerse-global.de
With nearly a third of its freely traded shares sold short and a single clinical trial outcome hanging over its future, Sellas Life Sciences has become a battleground stock of rare intensity. The company’s phase 3 REGAL study for its immunotherapy Galinpepimut-S in acute myeloid leukemia has recorded 78 of the 80 deaths required to trigger the final analysis. Until the remaining two events occur — expected by high summer — the stock remains a pure binary bet, one that has already produced eye-popping returns.
The share price closed Friday at €12.85, down 1.91% on the day but still up 19.53% over the past week, 81.50% over the past month, and a stunning 593.84% year on year. The 52-week high of €15.25 was reached on June 30, only to give back roughly 15.74% since then as profit-taking set in. The annualized 30-day volatility stands at 124.24%, a figure that captures the market’s frayed nerves.
Takeover Signals Meet a Record Short Squeeze
Much of the recent volatility stems from a cocktail of takeover speculation and heavy short interest. Sellas amended the employment agreements of CEO Angelos Stergiou, CFO John Burns and Chief Development Officer Dragan Cicic, adding change-of-control clauses that promise lump-sum severance payments. Burns and Cicic would each receive 15 months’ salary if terminated after a change in control. These golden parachute provisions ignited rumors that the company is courting a buyer or a licensing deal — though no formal transaction has been announced.
While the rumor mill spins, short sellers have piled in. The short interest climbed to nearly 33% of the float as of June 15, up from 28.4% at the start of the year. That elevated level sets the stage for a potential squeeze if the REGAL data come out positive, but also amplifies downside risk if the trial disappoints. Two fair-value estimates from the Simply Wall St community illustrate how polarized opinions are: one analyst sees the stock worth $1 per share, another $10.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Financial Cushion and a Second Pipeline Asset
Sellas has fortified its balance sheet. As of March 31, 2026, the company held more than $107.1 million in cash, supplemented by a $150 million at-the-market equity facility that remains untapped. In the second quarter, $7.5 million flowed in from exercised warrants. The net loss for the first quarter was $8.4 million — typical for a pre-revenue biotech. The cash runway is expected to extend past the REGAL data readout, reducing the risk of near-term dilution.
Beyond Galinpepimut-S, the company is developing a CDK9 inhibitor called SLS009, with new safety and efficacy data scheduled for summer 2026. That readout will arrive around the same time as the REGAL results but has so far received less attention from traders.
Technicals Flash Overbought, Fundamentals Unhinged
The 14-day relative strength index sits at 72.0, firmly in overbought territory. The stock trades 82.80% above its 50-day moving average of €7.03, 130.70% above the 100-day average and 244.97% above the 200-day average — all hallmarks of an extended rally driven by sentiment rather than fundamentals. The price-to-book ratio of roughly 25.6 dwarfs the biotech sector average of 2.7.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
Analyst consensus targets the stock at just €8.74, implying a 32% discount from current levels. That gap between market euphoria and analyst caution is typical for biotechs waiting on a pivotal data point. Until the 80th event is recorded and the REGAL top-line results are disclosed — likely in late Q3 or Q4 2026 — Sellas will remain a high-octane speculation play, one where a single hazard ratio can either validate the rally or trigger a brutal correction.
Ad
Sellas Life Sciences Stock: New Analysis - 4 July
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
